Followers | 88 |
Posts | 5661 |
Boards Moderated | 1 |
Alias Born | 07/06/2014 |
Monday, January 31, 2022 4:53:16 PM
Recent ALZN News
- Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s • Business Wire • 10/16/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/15/2024 08:30:38 PM
- Alzamend Neuro Regains Compliance with Nasdaq Listing Standards • Business Wire • 10/15/2024 12:00:00 PM
- Alzamend Neuro CEO Stephan Jackman to Participate in the Maxim Group’s Virtual Healthcare Conference • Business Wire • 10/10/2024 12:00:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 10/03/2024 08:40:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/03/2024 08:30:12 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 09/11/2024 08:30:38 PM
- Alzamend Neuro Issues Letter to Stockholders • Business Wire • 08/26/2024 12:00:00 PM
- Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder • Business Wire • 08/19/2024 12:00:00 PM
- Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Major Depressive Disorder • Business Wire • 08/12/2024 12:00:00 PM
- Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Bipolar Disorder • Business Wire • 08/06/2024 12:00:00 PM
- Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, involving Patients with Alzheimer’s Disease • Business Wire • 08/05/2024 01:09:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2024 08:30:22 PM
- Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement • Business Wire • 07/31/2024 12:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 07/30/2024 08:30:39 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 07/30/2024 10:00:52 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/12/2024 08:30:23 PM
- Alzamend Neuro Announces Reverse Stock Split • Business Wire • 07/12/2024 12:00:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 07/10/2024 12:52:03 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 07/10/2024 04:15:12 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/08/2024 08:30:20 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 06/11/2024 08:30:19 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 06/03/2024 08:30:49 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 05/31/2024 08:59:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2024 08:30:23 PM
Kona Gold Beverage, Inc. Updates Multi-Million Dollar Merger and Posts Over $1.2 Million in Q3 Revenues • KGKG • Nov 15, 2024 10:36 AM
HealthLynked Corp. Announces Third Quarter and Year-to-Date 2024 Results with Strategic Restructuring, Third-Party Debt Repayment, and Core Technology Focus • HLYK • Nov 15, 2024 8:00 AM
Alliance Creative Group (ACGX) Releases Q3 2024 Financial and Disclosure Report with an increase of over 100% in Net Income for 1st 9 months of 2024 vs 2023 • ACGX • Nov 14, 2024 8:30 AM
Unitronix Corp. Publishes Its Cryptocurrency Portfolio Strategy • UTRX • Nov 14, 2024 8:05 AM
Avant Technologies and Ainnova Tech Form Joint Venture to Advance Early Disease Detection Using Artificial Intelligence • AVAI • Nov 12, 2024 9:00 AM
Swifty Global Announces Launch of Swifty Sports IE, Expanding Sports Betting and Casino Services in the Irish Market • DRCR • Nov 12, 2024 9:00 AM